DISCOVERY OF POTENT, ORALLY ACTIVE COMPOUNDS OF TYROSINE KINASE AND SERINE/THREONINE-PROTEIN KINASE INHIBITOR WITH ANTI-TUMOR ACTIVITY IN PRECLINICAL ASSAYS

Authors

  • Yun-Qing Qiu the First Affiliated Hospital, School of Medicine, Zhejiang University
  • Jue Zhou College of Food Science and Biotechnology, Zhejiang Gongshang University
  • Xin-Shan Kang Zhejiang Beta Pharma Co., Ltd
  • Jian-Zhong Shen-Tu
  • Lie-Ming Ding
  • Fen-Lai Tan
  • Jing Guo
  • Lan-Juan Li

Keywords:

Tyrosine kinase inhibitors, Serine/threonine-protein kinase inhibitors, Sorafenib, Clinical hepatotoxicity.

Abstract

Traditional medicines have become the most productive source of leads for drugs development, particularly as anti-cancer agents. Various screening approaches are being applied. Sorafenib, a multikinase inhibitor, is used to treat primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer. A small library of compounds analogous to sorafenib were designed and screened for the treatment of liver cancer. Multiple members of the family in an assay panel of tyrosine kinase family and serine/threonine-protein kinase family, including VEGFR, Abl, Aurora A, p 38, Lck, Src, PDGFR, Flt3, c-RAF, c-KIT, MEK(MAPKK) were selected to test these compounds. Analysis of the selectivity patterns for these compounds shows specificity for many kinase families. IC50 were measured for the selected compounds. Multiple compounds have very similar kinase inhibition profiles of VEGFR, Flt3, FGFR to that of sorafenib. The IC50 of c-RAF of BB1 is lower than sorafenib. The IC50 of c-RAF of BB3-12 is higher than that of sorafenib. For Flt3, IC50 of BB1-4 is less than sorafenib. The IC50 value of KDR of BB1-10 is less than sorafenib. especially against c-RAF, PDGFR, c-KIT, KDR compared to sorafenib. These compounds are potent Raf1 and Flt4 kinase inhibitors.

Downloads

Published

2012-02-03

How to Cite

Qiu, Y.-Q., Zhou, J., Kang, X.-S., Shen-Tu, J.-Z., Ding, L.-M., Tan, F.-L., Guo, J., & Li, L.-J. (2012). DISCOVERY OF POTENT, ORALLY ACTIVE COMPOUNDS OF TYROSINE KINASE AND SERINE/THREONINE-PROTEIN KINASE INHIBITOR WITH ANTI-TUMOR ACTIVITY IN PRECLINICAL ASSAYS. African Journal of Traditional, Complementary and Alternative Medicines, 9(3), 431–439. Retrieved from https://journals.athmsi.org/index.php/ajtcam/article/view/1422

Issue

Vol. 9 No. 3 (2012)

Section

Research Papers

License

Copyright: Creative Commons Attribution CC.

This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. View License Deed | View Legal Code Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications.